An observational study in HPV Vaccine, HPV Infection and HIV-1-infection, sponsored by Kenya Medical Research Institute. Completed at 1 site in Kenya. Open to participants aged 9 Years to 14 Years. Per ClinicalTrials.gov, last updated 2021-01-15.
Sponsored by Kenya Medical Research Institute · Observational
Longitudinal observational cohort study and extension of the MISP ID: 38406 'immunogenicity and safety of quadrivalent human papillomavirus vaccine in HIV-infected pre-adolescent girls and boys in Kenya'.
We evaluated for persistence of HPV antibody by measuring titers to specific HPV types 6, 11, 16 and 18 at re-enrollment month 24 , 36 and 48 months in addition to month 7 and 12, after initial vaccination. This provided data for immunogenicity among HIV-infected children for approximately 48 months after initial vaccination. We assessed decline over study intervals in HPV type-specific antibodies.
6,688 studies on the registry are indexed under Infections; 807 are open to participants now.
This study's enrollment of 176 is below the median of 240 across 2,136 observational studies indexed under Infections.
Browse Infections studies →Kenya Medical Research Institute is the lead sponsor of 13 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
HIV-1 infected boys and girls who had received 3 doses of QHPV vaccine
Exclusion Criteria:
Intramuscular injection with 3 doses of QHPV
Also known as: QHPV vaccine
Human Papillomavirus Antibody Titers
Geometric mean titers for HPV type -6, -11, -16 and -18
Time frame: 48 months
HIV RNA viral load
Impact of HIV RNA viral load on HPV antibody response
Time frame: 48 months
CD 4 cell count
Impact of immune status on HPV antibody response
Time frame: 48 months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kenya Medical Research Institute